Lymphokine-activated killer (LAK) cells from human intestinal mucosa: Cytotoxic activity against tumor cell lines and modified self but not autologous and allogeneic colon cancer cells (Q54385774)

From Wikidata

Jump to navigation Jump to search

scientific article published on April 1, 1988

Language	Label	Description	Also known as
English	Lymphokine-activated killer (LAK) cells from human intestinal mucosa: Cytotoxic activity against tumor cell lines and modified self but not autologous and allogeneic colon cancer cells	scientific article published on April 1, 1988

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

29 May 2018

http://europepmc.org/abstract/MED/3361887

Lymphokine-activated killer (LAK) cells from human intestinal mucosa: Cytotoxic activity against tumor cell lines and modified self but not autologous and allogeneic colon cancer cells (English)

1 reference

10.1016/0022-4804(88)90188-6

https://api.crossref.org/works/10.1016/0022-4804(88)90188-6

1 January 2023

1 reference

based on heuristic

inferred from title

1 reference

10.1016/0022-4804(88)90188-6

https://api.crossref.org/works/10.1016/0022-4804(88)90188-6

1 January 2023

Victor Warren Fazio

4

object named as

Fazio VW

1 reference

Europe PubMed Central

PubMed publication ID

29 May 2018

http://europepmc.org/abstract/MED/3361887

author name string

J. L. Trudel

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A3361887

1 January 2023

K. R. Youngman

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A3361887

1 January 2023

G. A. West

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A3361887

1 January 2023

C. Fiocchi

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A3361887

1 January 2023

language of work or name

1 reference

National Center for Biotechnology Information

PubMed publication ID

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=3361887

1 January 2023

publication date

1 April 1988

1 reference

Europe PubMed Central

PubMed publication ID

29 May 2018

http://europepmc.org/abstract/MED/3361887

full work available at URL

https://api.elsevier.com/content/article/PII:0022480488901886?httpAccept=text/xml

1 reference

10.1016/0022-4804(88)90188-6

https://api.crossref.org/works/10.1016/0022-4804(88)90188-6

1 January 2023

https://api.elsevier.com/content/article/PII:0022480488901886?httpAccept=text/plain

1 reference

10.1016/0022-4804(88)90188-6

https://api.crossref.org/works/10.1016/0022-4804(88)90188-6

1 January 2023

language of work

Journal of Surgical Research

1 reference

Europe PubMed Central

PubMed publication ID

29 May 2018

http://europepmc.org/abstract/MED/3361887

44

1 reference

Europe PubMed Central

PubMed publication ID

29 May 2018

http://europepmc.org/abstract/MED/3361887

4

1 reference

Europe PubMed Central

PubMed publication ID

29 May 2018

http://europepmc.org/abstract/MED/3361887

445-454

1 reference

Europe PubMed Central

PubMed publication ID

29 May 2018

http://europepmc.org/abstract/MED/3361887

Prolongation of the disease-free interval in surgically treated rectal carcinoma

1

1 reference

10.1016/0022-4804(88)90188-6

https://api.crossref.org/works/10.1016/0022-4804(88)90188-6

1 January 2023

Adjuvant Therapy of Colon Cancer — Results of a Prospectively Randomized Trial

2

1 reference

10.1016/0022-4804(88)90188-6

https://api.crossref.org/works/10.1016/0022-4804(88)90188-6

1 January 2023

Prolongation of postoperative disease-free interval and survival in human colorectal cancer by B.C.G. or B.C.G. plus 5-fluorouracil

3

1 reference

10.1016/0022-4804(88)90188-6

https://api.crossref.org/works/10.1016/0022-4804(88)90188-6

1 January 2023

A prospective controlled evaluation of combined pelvic radiotherapy and methanol extraction residue of BCG (MER) for locally unresectable or recurrent rectal carcinoma

4

1 reference

10.1016/0022-4804(88)90188-6

https://api.crossref.org/works/10.1016/0022-4804(88)90188-6

1 January 2023

Efficacy of MER immunotherapy when added to a regimen of 5-fluorouracil and methyl-CCNU following resection for carcinoma of the large bowel. A Veterans Administration Surgical Oncology Group report

5

1 reference

10.1016/0022-4804(88)90188-6

https://api.crossref.org/works/10.1016/0022-4804(88)90188-6

1 January 2023

Lymphokine-activated killer cells: a new approach to immunotherapy of cancer

6

1 reference

10.1016/0022-4804(88)90188-6

https://api.crossref.org/works/10.1016/0022-4804(88)90188-6

1 January 2023

Successful immunotherapy of natural killer-resistant established pulmonary melanoma metastases by the intravenous adoptive transfer of syngeneic lymphocytes activated in vitro by interleukin 2

7

1 reference

10.1016/0022-4804(88)90188-6

https://api.crossref.org/works/10.1016/0022-4804(88)90188-6

1 January 2023

Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes

10

1 reference

10.1016/0022-4804(88)90188-6

https://api.crossref.org/works/10.1016/0022-4804(88)90188-6

1 January 2023

Lymphokine-activated killer (LAK) cell phenomenon. IV. Lysis by LAK cell clones of fresh human tumor cells from autologous and multiple allogeneic tumors

11

1 reference

10.1016/0022-4804(88)90188-6

https://api.crossref.org/works/10.1016/0022-4804(88)90188-6

1 January 2023

Lysis of human solid tumor cells by lymphokine-activated natural killer cells

12

1 reference

10.1016/0022-4804(88)90188-6

https://api.crossref.org/works/10.1016/0022-4804(88)90188-6

1 January 2023

Lysis of primary hepatic tumours by lymphokine activated killer cells

13

1 reference

10.1016/0022-4804(88)90188-6

https://api.crossref.org/works/10.1016/0022-4804(88)90188-6

1 January 2023

High-dose recombinant interleukin 2 in the treatment of patients with disseminated cancer. Responses, treatment-related morbidity, and histologic findings

14

1 reference

10.1016/0022-4804(88)90188-6

https://api.crossref.org/works/10.1016/0022-4804(88)90188-6

1 January 2023

A new approach to the therapy of cancer based on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2

15

1 reference

10.1016/0022-4804(88)90188-6

https://api.crossref.org/works/10.1016/0022-4804(88)90188-6

1 January 2023

A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone

16

1 reference

10.1016/0022-4804(88)90188-6

https://api.crossref.org/works/10.1016/0022-4804(88)90188-6

1 January 2023

Constant-infusion recombinant interleukin-2 in adoptive immunotherapy of advanced cancer

17

1 reference

10.1016/0022-4804(88)90188-6

https://api.crossref.org/works/10.1016/0022-4804(88)90188-6

1 January 2023

Lymphokine-activated and natural killer cell activity in human intestinal mucosa

20

1 reference

10.1016/0022-4804(88)90188-6

https://api.crossref.org/works/10.1016/0022-4804(88)90188-6

1 January 2023

Isolation and functional characterization of human intestinal mucosal lymphoid cells

22

1 reference

10.1016/0022-4804(88)90188-6

https://api.crossref.org/works/10.1016/0022-4804(88)90188-6

1 January 2023

Partial purification of human colonic carcinoma cells by sedimentation

23

1 reference

10.1016/0022-4804(88)90188-6

https://api.crossref.org/works/10.1016/0022-4804(88)90188-6

1 January 2023

A rapid technique for isolation of viable tumor cells from solid tumors: use of the tumor cells for induction and measurement of cell-mediated cytotoxic responses

24

1 reference

10.1016/0022-4804(88)90188-6

https://api.crossref.org/works/10.1016/0022-4804(88)90188-6

1 January 2023

Characterization of a renal cell carcinoma cell line suitable as a target for immunological studies in vitro and in the nu/nu mouse

26

1 reference

10.1016/0022-4804(88)90188-6

https://api.crossref.org/works/10.1016/0022-4804(88)90188-6

1 January 2023

The human lymphokine-activated killer cell system. V. Purified recombinant interleukin 2 activates cytotoxic lymphocytes which lyse both natural killer-resistant autologous and allogeneic tumors and trinitrophenyl-modified autologous peripheral bloo

29

1 reference

10.1016/0022-4804(88)90188-6

https://api.crossref.org/works/10.1016/0022-4804(88)90188-6

1 January 2023

Generation of lymphokine-activated killer (LAK) cells from tumor-infiltrating lymphocytes

35

1 reference

10.1016/0022-4804(88)90188-6

https://api.crossref.org/works/10.1016/0022-4804(88)90188-6

1 January 2023

A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes

36

1 reference

10.1016/0022-4804(88)90188-6

https://api.crossref.org/works/10.1016/0022-4804(88)90188-6

1 January 2023

Identifiers

10.1016/0022-4804(88)90188-6

1 reference

Europe PubMed Central

PubMed publication ID

29 May 2018

http://europepmc.org/abstract/MED/3361887

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

29 May 2018

http://europepmc.org/abstract/MED/3361887

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q54385774&oldid=1799779624"